Trial Name: SWOG E5597
Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I, Non-Small Cell Lung Cancer
Trial Description:
Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The purpose of this study is to determine the effectiveness of selenium in preventing the development of second primary lung tumors in patients who have undergone surgery to remove stage I non-small cell lung cancer.
Treatment Plan:
Patients will be randomized to one of two treatment arms:
1. Arm 1 - selenium yeast tablet (one tablet daily for 4 years)
2. Arm 2 - placebo yeast tablet ( one tablet daily for 4 years)
Patients:
- At least 18 years old
- At least 6 months, but no more than 3 years, since surgery to remove stage I, non-small cell lung cancer
- No evidence of lung cancer after surgery
- No previous chemotherapy or radiation therapy for lung cancer
- Lab tests, a current physical and medical history must meet study specific criteria
This is a brief overview of this clinical trial and only selected eligibility criteria are listed.
If you are interested in receiving more information to see if you are eligible to participate in this study, please contact:
Mercy General Hospital, Rhoda Pineda at (916) 453-4651, or e-mail rpineda@chw.edu
Mercy San Juan Medical Center, Margaret Murphy at (916) 537-5109, or e-mail margaret.murphy2@chw.edu
